Navigation Links
Vion Reports 2008 Third Quarter and Nine-Month Results
Date:11/3/2008

vo poor-risk acute myelogenous leukemia. Clinical trials of laromustine (Cloretazine(R), VNP40101M) with cytarabine in elderly patients with acute myelogenous leukemia, with temozolomide in brain tumors, and with stem cell transplantation in advanced hematologic malignancies, are also being conducted. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. For additional information on Vion and its product development programs, visit the Company's Internet web site at http://www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's potential inability to file a New Drug Application or obtain regulatory approval for its products, particularly laromustine (Cloretazine,VNP40101M), delays in the regulatory approval process or delays or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies, clinical trials or interim clinical trial data are not predictive of safety and efficacy results in later or final clinical trials, the need for additional research and testing, the inability to manufacture product, the potential inability to secure external sources of funding to continue operations, the inability to access capital and funding on favorable terms, continued operating losses and the inability to continue operations as a result, and a variety of other risks set forth from time to time in Vion's filings with the Securities and Exchange Commission, including but not limited to the risks attendant to the forward-looking statements included under Item 1A, "Risk Factors" in Vion's Form 10-K for the year ended December 31, 2007 and Form 10-Q for the quarter ended June 30, 2008. In particular, there can be no assurance
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. AMICAS Reports Financial Results for the Third Quarter Ended September 30, 2008
2. Neovasc Reports Development Progress, Streamlined Operations and Issuance of Options
3. NxStage Reports Third Quarter 2008 Financial Results
4. Study reports Double Balloon Endoscopy useful for diagnosis and treatment of obscure GI bleeding
5. The Ensign Group, Inc. Reports Third Quarter 2008 Earnings; Reaffirms 2008 Guidance
6. Gen-Probe Reports Strong Financial Results for Third Quarter 2008, Raises Full-Year EPS Guidance
7. Poniard Pharmaceuticals Reports Third Quarter 2008 Financial Results and Corporate Update
8. Nuvelo Reports Third Quarter 2008 Financial Results
9. Claimsnet.com Reports Third Quarter 2008 Results
10. Remuda Ranch Reports Many Individuals With Eating Disorders Are Not Getting Help They Need
11. Palomar Medical Reports Financial Results for Third Quarter 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2015)... 2015 Adults who are not legally ... term or universal policies can now use the QuotesPros.com ... life insurance companies for single adults can now be ... http://quotespros.com/life-insurance.html . , The rate plans that nationwide agencies ... to a number of life protection policies. The term, ...
(Date:3/1/2015)... 01, 2015 A federal court ... ) scheduled to go to trial in October ... witness to provide testimony regarding the role an ... the Profemur device, Bernstein Liebhard LLP comments. According ... Northern District of Iowa on February 25th, Wright ...
(Date:3/1/2015)... March 01, 2015 The number of ... over the past few weeks in two New Jersey ... filing claims, the Firm announces. , A Case ... in the Bergen County proceeding established for products manufactured ... a few weeks earlier, when 90 fewer cases had ...
(Date:3/1/2015)... ERISAPros is pleased to announce ... the professional staff of its Compliance Department. , Evelyn ... State University-Mortiz College of Law. Prior to joining ERISAPros, ... several Fortune 500 companies as well as several privately ... Her experiences range from benefit plan design, vendor management, ...
(Date:3/1/2015)... 01, 2015 Theme and plugin developers ... transition pack for Final Cut Pro X entitled ... transitions to any FCPX editors project.” Said Christiana Austin, ... the tools needed to easily drag and drop their ... gets many different controls over the parameters of this ...
Breaking Medicine News(10 mins):Health News:Best Life Insurance Companies for Single Adults Now Searchable at Insurance Website 2Health News:Wright Profemur Hip Lawyers at Bernstein Liebhard LLP Comment on Court’s Decision Regarding Testimony Pertaining to Prototype for Profemur Hip Replacement 2Health News:Wright Profemur Hip Lawyers at Bernstein Liebhard LLP Comment on Court’s Decision Regarding Testimony Pertaining to Prototype for Profemur Hip Replacement 3Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 2Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 3Health News:Bernstein Liebhard LLP Comments on Case List Growth in New Jersey Transvaginal Mesh Litigations, Where Firm Attorneys are Representing Hundreds 4Health News:ERISAPros Recruits Evelyn King, J.D. and Carolyn Roddy, J.D. to its Professional Staff 2Health News:Announcing a New Transition Pack from Pixel Film Studios, Transccordion for Final Cut Pro X 2
... Websites with a Turn-Key Solution for Health Portal ... ... Jan. 16 HealthCare.com,( http://www.healthcare.com ), the leading healthcare provider directory ... MediResource ( http://www.mediresource.com ), a leading creator and,syndicator of interactive health ...
... (TSX:,DAX) (NASDAQ: DRAX ) has received approval from ... Course Issuer Bid (NCIB) to,purchase up to 4,072,054 common ... in the public float as at January 14, 2008.,As ... were issued and,outstanding., Purchases may begin on January ...
... Speeches and Ads During,Presidential Symposium at 2008 Winter ... prior to the primary,elections in the 2008 United ... Westen, Ph.D., will describe the,emotional way in which ... the American Psychoanalytic Association,s 2008 Winter Meeting.,Dr. Westen, ...
... PITTSBURGH, Jan. 16 It,s often hard for,children ... friends, but they,need friendship and play time as ... learn how to help ASD children foster friendships ... by the Hope Learning Center LLC, the conference ...
... directly linked to several diseases such as hypertension and type ... adipose tissues and may form a biochemical link between obesity ... insulin inhibits resistin mRNA level in 3T3-L1, which does not ... play a role in insulin resistance? Is insulin the major ...
... from Universit Lavals Faculty of Medicine and Robert-Giffard Hospital ... of antipsychotic drugswhich in extreme cases can be as ... avoided through a specially designed weight control program. The ... Tremblay report the details of their findings in a ...
Cached Medicine News:Health News:HealthCare.com & MediResource Partner to Distribute and License Health Content, Directory and Tools 2Health News:HealthCare.com & MediResource Partner to Distribute and License Health Content, Directory and Tools 3Health News:DRAXIS Share Buyback Approved by TSX 2Health News:DRAXIS Share Buyback Approved by TSX 3Health News:DRAXIS Share Buyback Approved by TSX 4Health News:2008 Presidential Campaign on the Couch 2Health News:PA Cyber Sponsors Conference on Helping Children With Autism Form Friendships 2Health News:Weight gain induced by antipsychotic drugs can be avoided 2
(Date:2/27/2015)... MARLTON, N.J. , Feb. 27, 2015  Acsis ... collaboration and serialization solutions, announced today that John ... as a Supply & Demand Chain Executive ... chain executives who are leading initiatives to help prepare ... challenges of today,s business climate. This year,s list of ...
(Date:2/27/2015)... 2015 Isis Pharmaceuticals, Inc. (Nasdaq: ... pro forma net operating loss (NOL) guidance and its ... position.  Isis, significantly improved financial results were due in ... payments the Company received from its partners.  Isis, pro ... nearly 60% improvement over its 2013 NOL of $40.2 ...
(Date:2/27/2015)... 2015 Report Details   ... trends, R&D progress, and predicted revenues ,Where is the ... the commercial prospects for this market and related technologies? ... other trends to 2025, discussing data, opportunities and prospects. ... regenerative medicine : cell-based therapies that aim to ...
Breaking Medicine Technology:Acsis CSO John DiPalo Named Supply & Demand Chain Executive 2015 Pro to Know 2Isis Reports Financial Results and Highlights for 2014 2Isis Reports Financial Results and Highlights for 2014 3Isis Reports Financial Results and Highlights for 2014 4Isis Reports Financial Results and Highlights for 2014 5Isis Reports Financial Results and Highlights for 2014 6Isis Reports Financial Results and Highlights for 2014 7Isis Reports Financial Results and Highlights for 2014 8Isis Reports Financial Results and Highlights for 2014 9Isis Reports Financial Results and Highlights for 2014 10Isis Reports Financial Results and Highlights for 2014 11Isis Reports Financial Results and Highlights for 2014 12Isis Reports Financial Results and Highlights for 2014 13Isis Reports Financial Results and Highlights for 2014 14Isis Reports Financial Results and Highlights for 2014 15Isis Reports Financial Results and Highlights for 2014 16Isis Reports Financial Results and Highlights for 2014 17Translational Regenerative Medicine: Market Prospects 2015-2025 2Translational Regenerative Medicine: Market Prospects 2015-2025 3Translational Regenerative Medicine: Market Prospects 2015-2025 4Translational Regenerative Medicine: Market Prospects 2015-2025 5Translational Regenerative Medicine: Market Prospects 2015-2025 6Translational Regenerative Medicine: Market Prospects 2015-2025 7Translational Regenerative Medicine: Market Prospects 2015-2025 8
... May 10, 2011 Omeros Corporation (NASDAQ: ... and commercializing products focused on inflammation, coagulopathies and disorders ... results for the first quarter of 2011. ... ended March 31, 2011 were $7.7 million compared to ...
... 2011 Pierrel Research USA, Inc. ( www.pierrel-research-usa.com ... global pharmaceutical services company ( www.pierrel.it ), announces ... with epinephrine 1:100,000 and Articaine hydrochloride 4% with ... of Articaine with epinephrine, an injectable dental anesthetic ...
Cached Medicine Technology:Omeros Corporation Reports First Quarter 2011 Financial Results 2Omeros Corporation Reports First Quarter 2011 Financial Results 3Omeros Corporation Reports First Quarter 2011 Financial Results 4Pierrel Research USA Launches Orabloc™ a New Purer Articaine 2Pierrel Research USA Launches Orabloc™ a New Purer Articaine 3
... The 5mm AEM Laparoscopic Instruments incorporate ... AEM Instruments are shielded and monitored to ... of the instrument caused by insulation failure ... risk. The protective shield built into all ...
... The 5mm AEM Laparoscopic Instruments incorporate ... AEM Instruments are shielded and monitored to ... of the instrument caused by insulation failure ... risk. The protective shield built into all ...
... AEM Laparoscopic Instruments incorporate a layered design ... shielded and monitored to prevent stray electrosurgical ... caused by insulation failure or capacitive coupling; ... shield built into all AEM Instruments provides ...
... AEM Laparoscopic Instruments incorporate a layered design ... shielded and monitored to prevent stray electrosurgical ... caused by insulation failure or capacitive coupling; ... shield built into all AEM Instruments provides ...
Medicine Products: